Prospective, Multi-center, Randomized, Heparin-controlled Dose-finding Trial to Evaluate the Efficacy and Safety of Rivaroxaban, a Direct Factor Xa Inhibitor, on the Background of Standard Dual Antiplatelet Therapy to Support Elective Percutaneous Coronary Intervention.

Trial Profile

Prospective, Multi-center, Randomized, Heparin-controlled Dose-finding Trial to Evaluate the Efficacy and Safety of Rivaroxaban, a Direct Factor Xa Inhibitor, on the Background of Standard Dual Antiplatelet Therapy to Support Elective Percutaneous Coronary Intervention.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Heparin
  • Indications Myocardial infarction; Myocardial ischaemia; Thrombosis
  • Focus Therapeutic Use
  • Acronyms X-PLORER
  • Sponsors Bayer
  • Most Recent Events

    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Feb 2013 Planned end date changed from 1 Feb 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top